Maze Therapeutics (MAZE) Tax Provisions (2024 - 2025)

Maze Therapeutics (MAZE) reported Tax Provisions of -$27.5 million for Q4 2025, down 381.89% on a YoY basis from $9.8 million in Q4 2024, and down 381.89% sequentially from $9.8 million in Q4 2024.

Maze Therapeutics (MAZE) Tax Provisions (2024 - 2025) Analysis & Trends

Maze Therapeutics (MAZE) has 2 years of Tax Provisions data on file, last reported at -$27.5 million in Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 381.89% year-over-year to -$27.5 million; the trailing twelve-month figure through Dec 2025 stood at -$17.8 million (changed N/A YoY), and the FY2025 full-year result was -$27.5 million, down 345.52% from the prior year.
  • Tax Provisions fell to -$27.5 million in Q4 2025, from $9.8 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $9.8 million in Q4 2024 to a low of -$27.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Taxes (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 125,146.46
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -859,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 31.86 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 221.50 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 104.00 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -60.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Maze Therapeutics 1.49 Bn 1.49 Bn 18.21 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -27.54 Mn
Dec 31, 2024 9.77 Mn
Sep 30, 2024 -300,000.00
Jun 30, 2024 1.73 Mn